Tab Application Banner
  • Users Online: 781
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2019  |  Volume : 14  |  Issue : 1  |  Page : 28-31

Serum sclerostin levels in rheumatoid arthritis and correlation with disease activity and bone mineral density


Department of Rheumatology, King George's Medical University, Lucknow, Uttar Pradesh, India

Correspondence Address:
Dr. Rasmi Ranjan Sahoo
King George's Medical University, Lucknow - 226 003, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/injr.injr_113_18

Rights and Permissions

Background: This study aims to assess serum sclerostin, an inhibitor of the Wnt/β-catenin signaling pathway, in rheumatoid arthritis (RA) and its correlation with disease activity and bone mineral density (BMD). Methods: RA patients (>18 years) fulfilling the ACR/EULAR (2010) criteria for RA were included. Postmenopausal women, those with other autoimmune diseases, secondary causes of osteoporosis, severe vitamin D deficiency, chronic liver disease, chronic kidney disease stage 3 and above, and those patients on anticonvulsants were excluded. Rheumatoid factor, anticitrullinated protein antibody, 25-OH Vitamin D estimation, plain radiographs of hands, and BMD measurement by dual-energy X-ray absorpiometry were done in patients. Disease activity was assessed by clinical disease activity index (CDAI). Serum sclerostin levels in RA patients and controls (age and sex matched) were measured by commercial enzyme-linked immunosorbent assay (ELISA) and the relationship of sclerostin with low BMD, ESR, CDAI, and erosion were explored. Results: The mean age of patients (n = 47) was 32.7 ± 6.8 years and mean disease duration was 4.2 ± 2 years. All patients were women, mean body mass index was 22.38±4.4 and mean vitamin D level was 27.9±16.4 ng/ml. 25.5% of RA patients had low BMD at least one site (Z-score: −2 or less). Serum sclerostin was significantly higher in patients compared to controls (8422 ± 3655 pg/ml vs. 6479 ± 1510 pg/ml, P = 0.002). Serum sclerostin levels did not correlate significantly with ESR (r = −0.31 and P = 0.048), CDAI (r = −0.11 and P = 0.45), BMD at lumbar spine (L1–L4, r = 0.14, and P = 0.35), femur neck (r = 0.06 and P = 0.67), and wrist (r = 0.12 and P = 0.41). Conclusion: Serum sclerostin levels were elevated in RA patients but did not correlate with disease activity and BMD.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed704    
    Printed20    
    Emailed0    
    PDF Downloaded70    
    Comments [Add]    

Recommend this journal